<DOC>
	<DOCNO>NCT02547519</DOCNO>
	<brief_summary>Type 1 diabetes ( T1D ) result autoimmune destruction insulin-producing beta cell within pancreatic islet Langerhans . This process identify circulate islet autoantibody beta cell antigen , mediate lack immunological self-tolerance . Self-tolerance achieve T cell exposure antigen thymus periphery manner delete autoreactive effector T cell induce regulatory T cell . Immunological tolerance achieve administration antigen appropriate condition . Administration oral insulin islet autoantibody-negative child genetically predispose T1D offer potential induce immunological tolerance beta cell thereby protect development islet autoimmunity T1D .</brief_summary>
	<brief_title>Pre-POINT-Early Study</brief_title>
	<detailed_description>The purpose Pre-POINT-Early Study investigate consolidate find precede Pre-POINT Study , namely safety immune efficacy daily dose 67.5 mg oral insulin . Since young child test Pre-POINT-Early , 67.5 mg dose reach dose escalation start 7.5 mg 3 month follow exposure 22.5 mg 3 month , reach desire 67.5 mg dose , administer 6 month 22 child . The active substance oral application human insulin , synthesize special non-disease-producing laboratory strain Escherichia coli bacteria genetically alter addition gene human insulin production ( Lilly Pharmaceuticals , Indianapolis , Indiana , USA ) . The physical , chemical pharmaceutical property human insulin well documented manufacturer . Oral Insulin apply capsule contain 7.5 ; 22.5 67.5 mg active substance together fill substance cellulose . After oral administration insulin rapidly degrade gastric acid . Enteric delivery systemic availability therefore unlikely efficacy active insulin likely restrict oral mucosa . In human study oral insulin administration safe without adverse side effect dose 2.5 7.5 mg per day . Additionally Bonifacio et al . conduct complete Pre-POINT study , first primary autoantigen vaccination dose-finding study child high genetic risk type 1 diabetes administer insulin orally daily . Oral insulin test dos ( 2.5 mg ; 7.5 mg ; 22.5 mg 67.5 mg ) Pre-POINT consider safe : None child receive study drug placebo experience hypoglycaemic episode administration medication , allergic reaction observe . The Pre-POINT-Early intended dos oral application 7.5 , 22.5 67.5 mg per day . The aim study determine whether daily administration oral insulin start dose 7.5 mg ( 3 month ) , move dose 22.5 mg ( 3 month ) high dose 67.5 mg ( 6 month ) insulin young child age 6 month 2 year high genetic risk T1DM induces immune response insulin and/or proinsulin feature immune regulation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Children age 6 month 2 year first degree relative type 1 diabetes , HLA genotype include HLA DR4DQB1*0302 HLA DR4DQB1*0304 haplotype , include one follow allele haplotype : DR 11 , DR 12 , DQB1*0602 , DR7DQB1*0303 , DR14DQB1*0503 must 2 . Islet autoantibody negative time recruitment . 1 . Concomitant disease treatment , may interfere assessment cause immunosuppression , judge investigator . 2 . Prior current participation another intervention trial . 3 . Any condition could associate poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>oral insulin</keyword>
	<keyword>oral tolerance</keyword>
	<keyword>autoantigen</keyword>
	<keyword>self tolerance</keyword>
	<keyword>prevention</keyword>
	<keyword>risk develop type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
</DOC>